A multicentre validation study of the diagnostic value of plasma neurofilament light

• DOI: 10.1038/s41467-021-23620-z
• Publication Date: 2021-06-07T10:20:51Z
• Authors: Nicholas J. Ashton; Shorena Janelidze; Ahmad Al Khleifat; Antoine Leuzy; Emma L. van der Ende; Thomas K. Karikari; Andrea L. Benedet; Tharick A. Pascoal; Alberto Lleó; Lucilla Parnetti; Daniela Galimberti; Laura Bonanni; Andrea Pilotto; Alessandro Padovani; Jan Lycke; Lenka Novakova; Markus Axelsson; Latha Velayudhan; Gil D. Rabinovici; Bruce Miller; Carmine Pariante; Naghmeh Nikkheslat; Susan M. Resnick; Madhav Thambisetty; Michael Schöll; Gorka Fernández-E...; Francisco J. Gil-Bea; Adolfo López de M...; Ammar Al-Chalabi; Pedro Rosa-Neto; Andre Strydom; Per Svenningsson; Erik Stomrud; Alexander Santillo; Dag Aarsland; John C. van Swieten; Sebastian Palmqvist; Henrik Zetterberg; Kaj Blennow; Abdul Hye; Oskar Hansson
• Keywords: Depression

Increased cerebrospinal fluid neurofilament light (NfL) is a recognized biomarker for neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as marker of 13 neurodegenerative disorders, Down syndrome, depression and cognitively unimpaired controls from two multicenter cohorts: King's College London (n = 805) the Swedish BioFINDER study 1,464). Plasma was significantly increased all cortical amyotrophic lateral sclerosis atypical parkinsonian disorders. We demonstrate clinically useful identifying disorders patients with parkinsonism, dementia individuals among psychiatric frontotemporal cognitive impairment. Data-driven cut-offs highlighted fundamental importance age-related clinical younger age onset. Finally, performs best when applied to indicate no underlying neurodegeneration, low false positives, cut-offs.